% IMPORTANT: The following is UTF-8 encoded.  This means that in the presence
% of non-ASCII characters, it will not work with BibTeX 0.99 or older.
% Instead, you should use an up-to-date BibTeX implementation like “bibtex8” or
% “biber”.

@ARTICLE{Hemminki:293797,
      author       = {K. Hemminki$^*$ and F. Zitricky and A. Försti$^*$ and T.
                      Tapaninen and A. Hemminki and G. Juliusson and C. U.
                      Niemann},
      title        = {{C}omplex {R}elationships between {D}iagnostics and
                      {S}urvival in {C}hronic {L}ymphocytic {L}eukemia in
                      {D}enmark, {F}inland, {N}orway, and {S}weden.},
      journal      = {Cancers},
      volume       = {16},
      number       = {18},
      issn         = {2072-6694},
      address      = {Basel},
      publisher    = {MDPI},
      reportid     = {DKFZ-2024-01955},
      pages        = {3229},
      year         = {2024},
      note         = {#EA:Z999#},
      abstract     = {Chronic lymphocytic leukemia (CLL) is a common
                      hematological malignancy with highly variable clinical
                      presentation. Many patients never require any treatment but
                      for the others, chemotherapy, immunochemotherapy, and newer
                      targeted therapies have changed the treatment landscape.
                      Diagnostic age influences the applied treatment, and we thus
                      wanted to analyze age-specific survival trends through 50
                      years up to 2020s.We used 1- and 5-year relative survival
                      from the NORDCAN database, with data from Denmark (DK),
                      Finland (FI), Norway (NO), and Sweden (SE). Because of the
                      variable presentation of CLL, we also considered incidence
                      and mortality trends. For comparison, US SEER data were
                      used.The large age-specific survival differences in 1972-76
                      almost disappeared by 2017-21. While 5-year survival in
                      younger patients exceeded $90\%,$ for those diagnosed at age
                      80-89 years, survival reached $90\%$ in DK and SE women,
                      $80\%$ in NO and SE men, but only $50\%$ in FI. DK 5-year
                      overall survival for men was $92.4\%,$ and for women, it was
                      $96.3\%.$ These survival figures were higher than
                      age-group-specific US survival data.The DK data are probably
                      global top figures for national survival which could be
                      achieved by boosting survival even among the oldest
                      patients. The qualification to these figures and
                      international comparisons is that survival needs to be
                      considered in terms of incidence, which is high in DK and
                      NO. Low survival of the FI 80-89-year-old patients, even in
                      the first year after diagnosis, may suggest delayed
                      diagnosis, which should call for a closer national
                      scrutiny.},
      keywords     = {periodic survival (Other) / prognosis (Other) / targeted
                      agents (Other) / treatment (Other)},
      cin          = {Z999 / B062 / HD01},
      ddc          = {610},
      cid          = {I:(DE-He78)Z999-20160331 / I:(DE-He78)B062-20160331 /
                      I:(DE-He78)HD01-20160331},
      pnm          = {313 - Krebsrisikofaktoren und Prävention (POF4-313)},
      pid          = {G:(DE-HGF)POF4-313},
      typ          = {PUB:(DE-HGF)16},
      pubmed       = {pmid:39335200},
      pmc          = {pmc:PMC11429559},
      doi          = {10.3390/cancers16183229},
      url          = {https://inrepo02.dkfz.de/record/293797},
}